CA2912483C - Silica hydrogel composite - Google Patents

Silica hydrogel composite Download PDF

Info

Publication number
CA2912483C
CA2912483C CA2912483A CA2912483A CA2912483C CA 2912483 C CA2912483 C CA 2912483C CA 2912483 A CA2912483 A CA 2912483A CA 2912483 A CA2912483 A CA 2912483A CA 2912483 C CA2912483 C CA 2912483C
Authority
CA
Canada
Prior art keywords
hydrogel composite
silica hydrogel
silica
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2912483A
Other languages
English (en)
French (fr)
Other versions
CA2912483A1 (en
Inventor
Mika Jokinen
Harry Jalonen
Ari-Pekka Forsback
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DelSiTech Oy
Original Assignee
DelSiTech Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DelSiTech Oy filed Critical DelSiTech Oy
Publication of CA2912483A1 publication Critical patent/CA2912483A1/en
Application granted granted Critical
Publication of CA2912483C publication Critical patent/CA2912483C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0073—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form semi-solid, gel, hydrogel, ointment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Silicon Compounds (AREA)
CA2912483A 2013-06-24 2014-06-18 Silica hydrogel composite Active CA2912483C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20135685 2013-06-24
FI20135685 2013-06-24
PCT/FI2014/050492 WO2014207304A1 (en) 2013-06-24 2014-06-18 Silica hydrogel composite

Publications (2)

Publication Number Publication Date
CA2912483A1 CA2912483A1 (en) 2014-12-31
CA2912483C true CA2912483C (en) 2021-06-15

Family

ID=51178958

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2912483A Active CA2912483C (en) 2013-06-24 2014-06-18 Silica hydrogel composite

Country Status (14)

Country Link
US (1) US9949922B2 (cg-RX-API-DMAC7.html)
EP (1) EP3013317B1 (cg-RX-API-DMAC7.html)
JP (1) JP6433490B2 (cg-RX-API-DMAC7.html)
CN (1) CN105451713B (cg-RX-API-DMAC7.html)
AU (1) AU2014300888B2 (cg-RX-API-DMAC7.html)
CA (1) CA2912483C (cg-RX-API-DMAC7.html)
DK (1) DK3013317T3 (cg-RX-API-DMAC7.html)
ES (1) ES2768606T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20200134T1 (cg-RX-API-DMAC7.html)
HU (1) HUE047897T2 (cg-RX-API-DMAC7.html)
LT (1) LT3013317T (cg-RX-API-DMAC7.html)
PL (1) PL3013317T3 (cg-RX-API-DMAC7.html)
PT (1) PT3013317T (cg-RX-API-DMAC7.html)
WO (1) WO2014207304A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
PL3365020T3 (pl) * 2015-10-22 2020-03-31 Delsitech Oy Preparat depot kompozytu hydrożelowego
FI20155779A7 (fi) 2015-10-30 2017-05-01 Solani Therapeutics Ltd Ei-steroidaalisen anti-inflammatorisen lääkkeen hidastetusti vapautuva annostelu
WO2018102480A1 (en) * 2016-11-30 2018-06-07 Brown University Methods of fabricating hyper compliant polymer particles and methods of use and compositions
CA3088700A1 (en) * 2018-01-23 2019-08-01 Ascend Biopharmaceuticals Ltd Enhanced viral delivery formulation
US20210121534A1 (en) 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
AU2019290582A1 (en) 2018-06-19 2021-01-28 Cella Therapeutics, Llc Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-alpha (TNF-alpha) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease
KR20200051916A (ko) * 2018-11-05 2020-05-14 주식회사 메디포럼제약 고세렐린을 포함하는 실리카 하이드로겔 조성물
EP4009857B1 (en) * 2019-08-06 2025-08-20 DOSE Medical Corporation Bioerodible cross-linked hydrogel implants and related methods of use
CN111443012B (zh) * 2020-04-09 2021-07-20 华南理工大学 基于复合波等变率温度扫描流变的聚合物凝胶点表征方法
US20230250142A1 (en) 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
WO2022008804A1 (en) 2020-07-07 2022-01-13 Sartar Therapeutics Ltd Silica hydrogel composite and its use
IL301609A (en) * 2020-10-01 2023-05-01 Standard Millox Pharmaceuticals Oy Hydrogel material
US20240197623A1 (en) * 2021-04-07 2024-06-20 Stealth Bio Therapeutics Inc. Silica-based formulations of therapeutic oliogpeptides and peptidomimetics
KR20250092172A (ko) 2022-09-01 2025-06-23 옵티파이 테라퓨틱스 아게 안과용 조성물
AU2024304630A1 (en) 2023-06-15 2025-12-11 Delsitech Oy Injectable composite depot
WO2026083006A1 (en) 2024-10-18 2026-04-23 Delsitech Oy Silica hydrogel composite comprising an active agent
WO2026125822A1 (en) 2024-12-13 2026-06-18 Delsitech Oy Silica hydrogel composite with a water soluble additive

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332968A (en) * 1996-05-29 2000-08-25 Bioxid Oy A controllably dissolvable silica-xerogel prepared via sol-gel
DE10301669A1 (de) * 2003-01-17 2004-07-29 Gesellschaft zur Förderung von Medizin-, Bio- und Umwelttechnologien e.V. Bioaktive keramische Kompositmaterialien und Verfahren zu deren Herstellung
CA2555179A1 (en) 2004-02-27 2005-09-09 Delsitech Oy Method for preparing adjustably bioresorbable sol-gel derived sio2
GB0420016D0 (en) * 2004-09-09 2004-10-13 Leuven K U Res & Dev Controlled release oral delivery system
WO2007135224A2 (en) 2006-05-23 2007-11-29 Delsitech Oy Method for storing silica-based material, package produced with the method and use of package for packaging of silica-based products
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
US20090324695A1 (en) 2008-05-30 2009-12-31 Paul Ducheyne Biocompatible polymer ceramic composite matrices
KR101068873B1 (ko) 2008-11-28 2011-09-30 연세대학교 산학협력단 바이오마커가 고정된 실리카 나노입자를 함유하는 하이드로젤 및 그 제조방법
US9987225B2 (en) 2009-09-30 2018-06-05 Ottawa Hospital Research Institute Crosslinked hydrogels and related method of preparation

Also Published As

Publication number Publication date
EP3013317A1 (en) 2016-05-04
WO2014207304A1 (en) 2014-12-31
US20160136088A1 (en) 2016-05-19
CN105451713B (zh) 2019-04-23
HUE047897T2 (hu) 2020-05-28
PL3013317T3 (pl) 2020-05-18
US9949922B2 (en) 2018-04-24
ES2768606T3 (es) 2020-06-23
JP6433490B2 (ja) 2018-12-05
LT3013317T (lt) 2020-03-10
EP3013317B1 (en) 2019-12-04
PT3013317T (pt) 2020-02-19
CA2912483A1 (en) 2014-12-31
HRP20200134T1 (hr) 2020-08-21
AU2014300888B2 (en) 2019-01-17
AU2014300888A1 (en) 2015-12-10
DK3013317T3 (da) 2020-02-17
JP2016522243A (ja) 2016-07-28
CN105451713A (zh) 2016-03-30

Similar Documents

Publication Publication Date Title
WO2014194034A3 (en) Novel metalloproteases
WO2014206561A8 (en) Novel antibody frameworks
WO2014194117A3 (en) Novel metalloproteases
EP3060611A4 (en) Aqueous coating composition and process of making the same
EP3020760A4 (en) Propylene-based resin composition
JP2014010339A5 (cg-RX-API-DMAC7.html)
EP3000784A4 (en) Silica sol and silica-containing epoxy resin composition
WO2014199352A3 (en) Lipid-based platinum-n-heterocyclic carbene compounds and nanoparticles
WO2014086982A3 (en) Stable metal compounds, their compositions and methods of their use
WO2015079033A9 (de) Additionsverbindungen von polyaminen
EP2808235B8 (en) Inverted pendulum type vehicle
HK1223300A1 (zh) 皮质类固醇组合物
PL3068825T3 (pl) Wytwarzanie materiałów porowatych przez ekspansję żeli polimerowych
WO2015029074A3 (en) Compositions of eltrombopag
WO2014107578A8 (en) Homogeneous detergent composition
EP3016936A4 (en) Process for preparing clomazone, novel form and use of the same
MX2014005510A (es) Nuevas composiciones, produccion de las mismas y uso de las mismas para la produccion de poliamidas coladas.
WO2014091167A3 (fr) Composes cyclopropylboroniques, leur procede de preparation et leur utilisation
WO2016009401A3 (en) Preparation of tedizolid phosphate
WO2015003135A3 (en) Transparent photocatalyst coating and methods of manufacturing the same
WO2016008586A8 (en) Membrane with performance enhancing multi-level macroscopic cavities
WO2015051045A3 (en) 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE
IL240381A0 (en) A process for the isomerization of an external double bond
WO2014195861A3 (en) Preparation of ticagrelor
EP3038640A4 (en) Substituted urea depsipeptide analogs as activators of the clpp endopeptidase

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190110

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - SMALL

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250610

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250610

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - SMALL

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260611

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260611